Latest Phase 3 Data for First-in-Class TREMFYA ® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, December 3, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheumatic Diseases (ARD), evaluating this selective interleukin (IL)-23 inhibitor in adults with active psoriatic arthritis (PsA) who demonstrated inadequate efficacy or intolerance to tumor necrosis factor inhibition (TNFi).1 Results showed significantly higher proportions of patients treated with TREMFYA had improvement in joint signs and symptoms and complete skin clearance versus placeb...
Source: Johnson and Johnson - December 3, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
New Comprehensive Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years
SPRING HOUSE, PENNSYLVANIA, November 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced comprehensive efficacy and safety data from the DISCOVER–2 trial of TREMFYA® (guselkumab) were published in Arthritis & Rheumatology, representing the final results of the first two-year clinical trial investigating a selective interleukin (IL)-23 inhibitor therapy in active psoriatic arthritis (PsA).1 Results show a majority of TREMFYA-treated biologic-naïve adult patients with active PsA achieved improvements in joint signs and symptoms (American College of Rheumatology [ACR] 20/50/70)a a...
Source: Johnson and Johnson - November 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque psoriasis (P...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Cold Sores (Oral Herpes, Herpes Labialis)
Title: Cold Sores (Oral Herpes, Herpes Labialis)Category: Diseases and ConditionsCreated: 6/16/1999 12:00:00 AMLast Editorial Review: 9/2/2021 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - September 2, 2021 Category: Dermatology Source Type: news
MRI show brain changes linked to poorer encephalitis outcomes
MRI reveals brain changes in adults with herpes simplex encephalitis that ar...Read more on AuntMinnie.comRelated Reading:
ECR 2020: COVID-19's nonpulmonary manifestations
Researchers outline neurological signs of COVID-19
Brain MRI shows long-term adverse effects of West Nile virus
MRI finds something fishy in outbreak of brain infections
Creutzfeldt-Jakob disease on MRI often missed by radiologists (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 27, 2021 Category: Radiology Source Type: news
New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, June 2, 2021 – Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a selective IL-23 inhibitor in adult patients with active PsA, all of whom had demonstrated inadequate response or intolerance to TNFi.1 In the COSMOS Phase 3b study, significantly higher proportions of patients treated with TREMFYA showed joint symptom improvement and complete skin clearance versus placebo at week 24 in this true TNFi-IRa patient population, which is often more diffic...
Source: Johnson and Johnson - June 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Phase 3 Data Showed First-in-Class TREMFYA ® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust Joint Symptom Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA)
SPRING HOUSE, PENNSYLVANIA, April 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new Phase 3 data which showed TREMFYA® (guselkumab) sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through five years (252 weeks), a and improved disease activity and axial symptoms in adults with active psoriatic arthritis (PsA) through one year (52 weeks).1,2,3 These data are being presented at the American Academy of Dermatology Virtual Meeting Experience 2021, where Janssen will present a total of 22 abstracts. TREMFYA is t...
Source: Johnson and Johnson - April 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Worm infestation in intestine has a remote effect on viral defenses
(University of Bonn) Infection with parasitic intestinal worms (helminths) can apparently cause sexually transmitted viral in-fections to be much more severe elsewhere in the body. This is shown by a study led by the Universities of Cape Town and Bonn. According to the study, helminth-infected mice developed significantly more severe symptoms after infection with a genital herpes viruses (Herpes Simplex Virus). The researchers suspect that these results can also be transferred to humans. The results have now appeared in the journal Cell Host& Microbe. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2021 Category: International Medicine & Public Health Source Type: news
Deadly Brain Tumor: Survival Extended by Oncolytic Virus Product Deadly Brain Tumor: Survival Extended by Oncolytic Virus Product
Improved survival was seen in a small trial in which a genetically engineered version of herpes simplex virus was infused directly into high-grade gliomas.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Differences in herpes virus symptoms may relate to variations in strain gene expression
(Penn State) Why do some people with cold sores around their lips experience painful lesions, while others have no symptoms at all, yet still spread the virus? A new study conducted at Penn State finds that these differences could be due to variations in the way certain strains of herpes simplex (HSV-1) -- the virus that causes cold sores, as well as genital herpes -- activate gene expression in neurons. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 29, 2021 Category: Infectious Diseases Source Type: news
New Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
SPRING HOUSE, PENNSYLVANIA, March 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitisb and d...
Source: Johnson and Johnson - March 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
What Causes Herpes Cold Sores? New Research
Scientists may have discovered why cold sores caused by herpes simplex virus (HSV) are triggered by stress, illness and sunburn. (Source: WebMD Health)
Source: WebMD Health - February 17, 2021 Category: Consumer Health News Source Type: news
What Causes Herpes Cold Sore Flare-Ups? New Study Offers Clues
WEDNESDAY, Feb. 17, 2021 -- Scientists may have discovered why cold sores caused by herpes simplex virus (HSV) are triggered by stress, illness and sunburn.
The finding could lead to new ways to prevent recurring cold sores and herpes-related eye... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 17, 2021 Category: General Medicine Source Type: news
How to get rid of a cold sore - four quick tips
COLD SORES are an unfortunate side effect of feeling rundown and can affect people throughout their lives once infected. Here is how to get rid of and treat a cold sore. (Source: Daily Express - Health)
Source: Daily Express - Health - February 16, 2021 Category: Consumer Health News Source Type: news
